hotspot -WSS

hotspot

author：comprehensive 2025-09-06 02:12:57 - browse：25587

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： This gene therapy has record $4.25 million price. It's saved children.

WSS

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Bring on the sabbaticals for nurses

'Patient friction coefficient' can gauge a clinical trial's patient burden

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Chinese researcher claims birth of first gene

Drug repurposing or repositioning? The language matters

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Jerome Adams on the need for new antivirals for Covid

Diabetes management: Digital health tools fall short, study says

Hepatitis C has a cure — but many Americans still lack access to it

'The Exorcist' director William Friedkin dead at 87

Walensky prepares to leave CDC — and Congress — behind

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

leisure time

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

6 surprising facts about sugar

Cancer, immunology, HIV research ensnared in fetal tissue politics

This gene therapy has record $4.25 million price. It's saved children.

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

knowledge

focus

knowledge

hotspot